Uc Irvine Medical Center

Orange, California 92868-4080

13 studies enrolling now · 91 studies all time

What they study most

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, Acute Ischemic Stroke, Acute Lung Injury, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Respiratory Distress Syndrome, Adenocarcinoma, Adenocarcinoma, Papillary, Advanced Breast Cancer, Advanced Cancer, Advanced Gastric Cancer

Studies at this site

• ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) — Recruiting now
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting now
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — Recruiting now
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) — Recruiting now
• Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System — Recruiting now
• An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome — Recruiting now
• Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer — Recruiting now
• Anticoagulation in ICH Survivors for Stroke Prevention and Recovery — Recruiting now
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2 — Recruiting now
• Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection — Recruiting now
• A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) — Recruiting now
• Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis — Running, not enrolling
• Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia — Enrolling by invitation
• Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) — Running, not enrolling
• Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy — Enrolling by invitation
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Running, not enrolling
• Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury — Running, not enrolling
• Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone — Completed
• Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia — Stopped early
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Running, not enrolling
• NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer — Completed
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial — Running, not enrolling
• Multimodality Neuromonitoring in XLIF — Completed
• A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) — Completed
• Posterior Cervical Fixation Study — Enrolling by invitation
• A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease — Stopped early
• Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance — Completed
• M6-C Artificial Cervical Disc Two-Level IDE Pivotal Study — Running, not enrolling
• Caffeine Use in the Management of Preterm Infants — Running, not enrolling
• A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy — Completed
• P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation — Running, not enrolling
• A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma — Stopped early
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma — Completed
• Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer — Completed
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors — Completed
• AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke — Stopped early
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) — Completed
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors — Stopped early
• Multi-arm Optimization of Stroke Thrombolysis — Completed
• Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials — Completed
• A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations — Completed
• A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen — Completed
• Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma — NO_LONGER_AVAILABLE
• AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) — Completed
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis — Stopped early
• Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia — Stopped early
• Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors — Completed